<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_RNRDtBU">A Digital Software Support Platform for Hyperthyroidism Management in South Korea: Markov Simulation Model-Based Cost-Effectiveness Analysis</title>
				<funder>
					<orgName type="full">Korean Thyroid Association Clinical Research Award</orgName>
				</funder>
				<funder>
					<orgName type="full">National IT Industry Promotion Agency</orgName>
					<orgName type="abbreviated">NIPA</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/501100003665</idno>
				</funder>
				<funder ref="#_nwsv8U4">
					<orgName type="full">Ministry of Science and ICT</orgName>
				</funder>
				<funder ref="#_H8VbsB9">
					<orgName type="full">Ministry of SMEs and Startups (MSS, Korea)</orgName>
				</funder>
				<funder ref="#_GfEjfej #_ud9tZh7">
					<orgName type="full">unknown</orgName>
				</funder>
				<funder ref="#_PqbpBwt">
					<orgName type="full">Hankuk University of Foreign Studies Research Fund</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Jung</forename><forename type="middle">Hyun</forename><surname>Kim</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Jaeyong</forename><surname>Shin</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Institute for Innovation in Digital Healthcare , Yonsei University Health System , Seoul , Republic of Korea</note>
								<orgName type="department">Institute for Innovation in Digital Healthcare</orgName>
								<orgName type="institution">Yonsei University Health System</orgName>
								<address>
									<settlement>Seoul</settlement>
									<country key="KR">Republic of Korea</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Department of Preventive Medicine , Yonsei University College of Medicine , Seoul , Republic of Korea</note>
								<orgName type="department">Department of Preventive Medicine</orgName>
								<orgName type="institution">Yonsei University College of Medicine</orgName>
								<address>
									<settlement>Seoul</settlement>
									<country key="KR">Republic of Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Man</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>4</label> Translational-Transdisciplinary Research Center , Clinical Research Institute , Kyung Hee University Hospital at Gangdong , School of Medicine , Kyung Hee University , Seoul , Republic of Korea</note>
								<orgName type="department" key="dep1">Translational-Transdisciplinary Research Center</orgName>
								<orgName type="department" key="dep2">Clinical Research Institute</orgName>
								<orgName type="department" key="dep3">School of Medicine</orgName>
								<orgName type="institution" key="instit1">Kyung Hee University Hospital at Gangdong</orgName>
								<orgName type="institution" key="instit2">Kyung Hee University</orgName>
								<address>
									<settlement>Seoul</settlement>
									<country key="KR">Republic of Korea</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><roleName>PhD</roleName><forename type="first">Jae</forename><forename type="middle">Hoon</forename><surname>Moon</surname></persName>
							<email>jaehoon.moon@snu.ac.kr</email>
							<affiliation key="aff4">
								<note type="raw_affiliation"><label>5</label> Center for Artificial Intelligence in Healthcare , Seoul National University Bundang Hospital , Seongnam , Republic of Korea</note>
								<orgName type="department">Center for Artificial Intelligence in Healthcare</orgName>
								<orgName type="institution">Seoul National University Bundang Hospital</orgName>
								<address>
									<settlement>Seongnam</settlement>
									<country key="KR">Republic of Korea</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<note type="raw_affiliation"><label>6</label> THYROSCOPE INC , Ulsan , Republic of Korea</note>
								<orgName type="institution">THYROSCOPE INC</orgName>
								<address>
									<settlement>Ulsan</settlement>
									<country key="KR">Republic of Korea</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<note type="raw_affiliation"><label>7</label> Department of Internal Medicine , Seoul National University Bundang Hospital , Seoul National University College of Medicine , Seongnam-si , Gyeonggi-do , Republic of Korea</note>
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution" key="instit1">Seoul National University Bundang Hospital</orgName>
								<orgName type="institution" key="instit2">Seoul National University College of Medicine</orgName>
								<address>
									<settlement>Seongnam-si Gyeonggi-do</settlement>
									<country key="KR">Republic of Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<note type="raw_affiliation">Division of Tourism and Wellness , Hankuk University of Foreign Studies , Yongin , Republic of Korea</note>
								<orgName type="department">Division of Tourism and Wellness</orgName>
								<orgName type="institution">Hankuk University of Foreign Studies</orgName>
								<address>
									<settlement>Yongin</settlement>
									<country key="KR">Republic of Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<note type="raw_affiliation">Department of Internal Medicine Seoul National University Bundang Hospital , Seoul National University College of Medicine 82 , Gumi-ro 173 Beon-gil , Bundang-gu Seongnam-si , Gyeonggi-do , 13620 Republic of Korea</note>
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution" key="instit1">Seoul National University Bundang Hospital</orgName>
								<orgName type="institution" key="instit2">Seoul National University College of Medicine</orgName>
								<address>
									<addrLine>82 Gumi-ro 173 Beon-gil Bundang-gu Seongnam-si</addrLine>
									<postCode>13620</postCode>
									<settlement>Gyeonggi-do</settlement>
									<country key="KR">Republic of Korea</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_BJVvHkS">A Digital Software Support Platform for Hyperthyroidism Management in South Korea: Markov Simulation Model-Based Cost-Effectiveness Analysis</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">F1365F267DA2028E2826533CFB01134F</idno>
					<idno type="DOI">10.2196/56738</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T11:11+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term xml:id="_fh2ZXth">hyperthyroidism</term>
					<term xml:id="_hWsf3Cg">digital monitoring solution</term>
					<term xml:id="_w5PkKS7">wearable devices</term>
					<term xml:id="_aUwugdA">mobile-based monitoring</term>
					<term xml:id="_pQw63Fs">cost-effectiveness analysis</term>
					<term xml:id="_h8r6PAT">QALYs</term>
					<term xml:id="_tJ6c4yd">hyperthyroidism management</term>
					<term xml:id="_QcN8ea4">apps</term>
					<term xml:id="_tVVZVcC">applications</term>
					<term xml:id="_WGZPXRy">digital health</term>
					<term xml:id="_zX23D8h">digital technology</term>
					<term xml:id="_NbcAmEZ">digital interventions</term>
					<term xml:id="_fqpmMJn">SDG3:good health and well-being</term>
					<term xml:id="_ew5c68a">quality-adjusted life years</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_QG9RY7P">Background:</head><p xml:id="_6ESnrPg"><s xml:id="_tNUyqcR">The integration of wearable technology for heart rate monitoring offers potential advancements in managing hyperthyroidism by providing a feasible way to track thyroid function.</s><s xml:id="_P3e5fN6">Although digital health solutions are gaining traction in various chronic conditions, their cost-effectiveness in hyperthyroidism management requires deeper investigation.</s><s xml:id="_Ndfew7y">Objective: This study aimed to evaluate the cost-effectiveness of a wearable or mobile-based thyroid function digital monitoring solution for hyperthyroidism management and to make a comparison with the existing standard approach within the South Korean health care context.</s><s xml:id="_tvtqkTg">Methods: We developed a decision-analytic Markov microsimulation model to simulate the cost and effectiveness of digital monitoring in a cohort of 10,000 hypothetical hyperthyroidism patients aged 40 years.</s><s xml:id="_EEekeF8">The analysis was conducted from the perspective of the health care system, with a 4.5% annual discount rate applied to costs and effectiveness and an inflation adjustment to 2022 values.</s><s xml:id="_RhPRcfj">Model inputs were sourced from clinical studies, publicly available datasets, and expert input, with outcomes measured in quality-adjusted life years (QALYs).</s><s xml:id="_jwGzpCk">Cost-effectiveness was evaluated through incremental cost-effectiveness ratios (ICERs) and net monetary benefits (NMB), with additional deterministic and probabilistic sensitivity analyses performed to address input uncertainties.</s><s xml:id="_z2QJx4Z">Results: Integrating digital monitoring yielded an additional 0.32 QALYs per patient at an incremental cost of US $3143, resulting in an ICER of US $9804.30</s><s xml:id="_ENKDgkJ">per QALY, significantly below the South Korean willingness-to-pay threshold of US $32,255/QALY.</s><s xml:id="_9vS5wMg">The digitally supported group exhibited improved rates of long-term remission (22.68%, 2268/10,000) and reduced postremission relapse (17.87%, 1787/10,000) compared to standard care (17.48%, 1748/10,000 and 26.37%, 2637/10,000, respectively).</s><s xml:id="_mW9whcQ">Probabilistic sensitivity analysis showed that digital intervention was the preferred cost-effective strategy in 64.4% (6440/10,000) of iterations.</s><s xml:id="_hE36KNj">Subscription costs of the digital platform and the utility weight for thyroid-associated orbitopathy emerged as key factors affecting the ICER in sensitivity analyses.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_g8cXZmb">Conclusions:</head><p xml:id="_KjPWAXw"><s xml:id="_zGycbTS">The findings suggest that digital monitoring provides a cost-effective strategy for enhancing hyperthyroidism management, supporting sustained remission, and reducing relapse rates.</s><s xml:id="_fmkHkKP">As such, digital solutions could serve as a valuable</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="12" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
		<surface n="13" ulx="0.0" uly="0.0" lrx="595.28" lry="841.89"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_3DDPBxB">Introduction</head><p xml:id="_fVKHWcc"><s xml:id="_TPauPPB">An overactive thyroid, medically termed hyperthyroidism or thyrotoxicosis, occurs when the thyroid gland generates an excessive amount of thyroid hormones.</s><s xml:id="_csmXPYy">Graves disease (GD) is the most common etiology for hyperthyroidism, with an estimated annual incidence ranging from 20 to 50 cases per 100,000 persons <ref type="bibr" target="#b0">[1]</ref>.</s><s xml:id="_VgPwz4c">In 2018, the prevalence of hyperthyroidism was 0.25%, and the age-standardized incidence in South Korea was 40.3 and 105.5 per 100,000 men and women, respectively <ref type="bibr" target="#b1">[2]</ref>.</s><s xml:id="_UGthYCR">Hyperthyroidism leads to a range of symptoms and signs due to thyroid hormones' impact on multiple organs.</s><s xml:id="_y9u2jyA">These include fatigue, anxiety, palpitations, excessive sweating, intolerance to heat, disrupted sleep, tremor, diarrhea, and weight loss <ref type="bibr" target="#b2">[3]</ref>.</s><s xml:id="_fXXguyy">Hyperthyroidism can be diagnosed through a thyroid function test (TFT) that measures serum thyroid hormone concentrations, including free thyroxine, thyrotropin, and other clinical factors.</s><s xml:id="_RgY4hPE">However, due to the nonspecific symptoms of hyperthyroidism, the timing of TFTs is often delayed, resulting in the diagnosis of hyperthyroidism occurring after it has significantly progressed.</s><s xml:id="_se5fRg5">Therefore, having a straightforward and easily measurable parameter to predict thyroid function status would prove beneficial for the management of hyperthyroidism.</s></p><p xml:id="_ASxtqVh"><s xml:id="_9kNTsQd">Photoplethysmography uses infrared light to monitor changes in blood circulation volume.</s><s xml:id="_vwFy56y">This measurement offers valuable insights into the functioning of the cardiovascular system <ref type="bibr" target="#b3">[4]</ref>.</s><s xml:id="_Vczfabq">In recent times, the use of photoplethysmography technology for heart rate monitoring has gained popularity, primarily because it is easy to use and comfortable for wearers <ref type="bibr" target="#b4">[5]</ref>.</s><s xml:id="_VqxhcWG">Various studies assessing the precision of wrist-worn heart rate monitors have been conducted, demonstrating relatively accurate heart rate measurements, especially for resting heart rate <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b6">7]</ref>.</s><s xml:id="_xytHCEB">Collecting detailed longitudinal heart rate data and physical activity information using these wearable devices is straightforward, and such data can offer more insights than sporadic heart rate measurements.</s><s xml:id="_3JEwVZj">This capability enables the collection and analysis of more comprehensive and precise heart rate data, a crucial parameter that is affected by thyroid function status <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b8">9]</ref>.</s><s xml:id="_efE6Pxx">A medical software platform is under development that uses wearable technology to predict thyroid function state and assist in the management of thyroid dysfunction.</s><s xml:id="_vQjAZFQ">It includes a mobile app and web solution for this purpose and is currently pending regulatory approval.</s></p><p xml:id="_eeEdAdm"><s xml:id="_wQS9VCk">Despite the promising potential of wearable technology for managing thyroid dysfunction, there is limited research published on its actual impact concerning health care outcomes and overall costs.</s><s xml:id="_dk4f37C">Therefore, we aimed to assess the cost-effectiveness of introducing a wearable or mobile-based thyroid function digital monitoring solution for hyperthyroidism management (Figure <ref type="figure" target="#fig_0">1</ref>) driven by heart rate monitors commercialized as digital therapeutics and to compare it with the current standard approach.</s><s xml:id="_NMtxdsu">(A) Heart rates collected from a wearable device on each date (the date of referred thyroid function test and target date), and (B) the risk level of hyperthyroidism calculated for the target date is determined by comparing the heart rate distribution over N days, including the target date, with the heart rate distribution over N days, including the day of the referred thyroid function test.</s><s xml:id="_vMUH8VH">In cases where the risk level surpasses the designated threshold, a notification is sent to the user, prompting them to seek medical attention.</s><s xml:id="_XMxyT8r">TFT: thyroid function test.</s></p><p xml:id="_rvsE8Z7"><s xml:id="_vKQF68f">50 70 90 110 Heart rates (bpm) Time (minute) 50 60 70 80 90 100 110 1 19 37 55 73 91 109 127 145 163 181 199 217 235 253 271 289</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_7fkDxfb">Chart Title</head><p xml:id="_qzvTAVF"><s xml:id="_4SJ4RxE">Heart rates (target date)</s></p><p xml:id="_f8zybj3"><s xml:id="_rPeQ6sR">Heart rates (referred TFT)</s></p><p xml:id="_bveYNTP"><s xml:id="_NzmfnPe">50 60 70 80 90 100 110 1 19 37 55 73 91 109 127 145 163 181 199 217 235 253 271 289 Chart Title Heart rates (target date) Heart rates (referred TFT) Risk level Time (day) Prediction: thyrotoxicosis Prediction: normal Increase in risk level (&gt; threshold) : alerts the user to seek attention A B</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_wwmF9kP">Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_zSu3aD4">Model Overview</head><p xml:id="_PExRtbF"><s xml:id="_y8ehUZ9">We constructed a decision-analytic Markov microsimulation model to simulate 10,000 iterations of the clinical course of patients with hyperthyroidism (Figure <ref type="figure" target="#fig_2">2</ref>).</s><s xml:id="_FctqHPJ">While a strict definition distinguishes between hyperthyroidism and GD, this paper refers to hyperthyroidism and conducts data analysis under this terminology.</s><s xml:id="_CGeZCuw">However, in South Korea, the incidence of toxic nodules as the underlying cause of hyperthyroidism is exceedingly low, accounting for less than 0.5% of cases <ref type="bibr" target="#b9">[10]</ref>.</s><s xml:id="_UScRCED">As a result, patient management in this study followed a protocol for GD.</s><s xml:id="_KF93Kgb">This model consists of several health states in which the simulated individual can be in and move between.</s><s xml:id="_AhV7WAv">The statistical definition of the model is a discrete-time stochastic process with the Markov property <ref type="bibr" target="#b10">[11]</ref>.</s><s xml:id="_Btn9XXU">The baseline cohort was comprised of 40-yearold individual patients with hyperthyroidism in South Korea.</s></p><p xml:id="_knU7gef"><s xml:id="_HyRa9dV">To advance time in our model, we used an annual cycle length, and the simulation continued until death or 100 years of age.</s><s xml:id="_DaWmmkz">The simulation of the natural disease progression and the effect of screening in men and women requires data including prevalence, incidence, risk of events, morbidity, and mortality.</s><s xml:id="_WpexFsd">The model captures the variability in individual patient responses to treatment and disease progression over time.</s><s xml:id="_JuEjDkz">Each iteration represents a single hypothetical patient moving through various health states based on probabilistic transitions, including remission, long-term remission, complications, hypothyroidism, relapse, long-term antithyroid drug (ATD) use, and death.</s><s xml:id="_6Dww9gp">Some proportion of patients remain in their current state (hypothyroid state), while others may transition to different health states, such as long-term remission or relapse requiring long-term ATD therapy to capture more realistic transitions between health states and better reflect the long-term impacts of treatments.</s><s xml:id="_nGG7cEv">Eventually, patients in any state could transition to an absorbing state, such as death.</s><s xml:id="_KM4bPBu">A lifetime Markov model was simulated over a total of 70 cycles with a one-year cycle length.</s><s xml:id="_5fvxtJq">Qualityadjusted life years (QALYs), which include both quantity (life-years gained) and quality (health-related quality of life incremental cost-effectiveness in utility value), were used as effectiveness variables.</s><s xml:id="_8WeVCKT">Incremental cost-effectiveness ratio (ICER) and incremental net monetary benefit were calculated to evaluate cost-effectiveness.</s><s xml:id="_sMNvbRW">By aggregating the outcomes from all 10,000 iterations, we estimate the overall clinical and economic impact of different strategies for hyperthyroidism.</s><s xml:id="_b58UZrS">Figure <ref type="figure" target="#fig_2">2</ref> depicts the core model, and the concept of combining time variables, treatment eligibility, and clinical prognosis was adapted from the previous studies.</s><s xml:id="_ubqWvBa">Patients with hyperthyroidism Digital intervention supported group Usual care Detected hyperthyroidism Nondetected hyperthyroidism No hyperthyroidism Antithyroid medication Remission Dead No need of treatment Treatment failure requires RAI or thyroidectomy Long-term remission Complications Hypothyroidism Relapse-long term ATD Dead Long-term remission Relapse-long term ATD Dead Stays current state National Health Insurance Service Claims Data A retrospective, population-based cohort study was conducted to investigate complications associated with hyperthyroidism and the related costs in Korea.</s><s xml:id="_64hd9W4">The study examined enrollment and claims data from individuals covered by the National Health Insurance Service (NHIS) between 2003 and 2015.</s><s xml:id="_EeJ7QCz">Patients with hyperthyroidism were defined as those who had 2 or more diagnostic codes of E05 or E06 and had been prescribed ATDs for at least 6 months.</s><s xml:id="_bMPtcT5">These drugs included MMI (191801ATB and 191802ATB), carbimazole (471501ATB, 471502ATB, and 471503ATB), and PTU (220101ATB and 220102ATB</s></p><p xml:id="_RvZ5egr"><s xml:id="_HWHkVZT">).</s><s xml:id="_ANyCwPq">The final cohort consisted of 1171 patients, excluding those who had taken medications for less than 6 months, were younger than 20 years, or had missing information (Multimedia Appendix 1).</s><s xml:id="_UDhTTTp">The major complications considered were thyroid-associated orbitopathy (TAO), heart failure, atrial fibrillation, osteoporosis, fractures, and thyroid cancer.</s><s xml:id="_R5Z8XJX">Direct medical costs, including physician and hospital reimbursements for treatment procedures, as well as the annual mean cost for each complication, were obtained from NHIS data (Table <ref type="table" target="#tab_1">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_5PapBWx">Intervention and Comparators</head><p xml:id="_T5qVc5U"><s xml:id="_gapebJG">To identify the potential effects of the digital monitoring solution used for hyperthyroidism management, we compared 2 strategies in this study.</s><s xml:id="_ZkWYrMB">In the control group, suspected patients with hyperthyroidism were diagnosed and treated with their usual care without using the digital solution, while the digitally supported group was assisted by the digital monitoring solution in the management and treatment of hyperthyroidism.</s><s xml:id="_una2jvy">We hypothesize that having a daily check of hormone status using this digital solution may lead to reduced hospital visits and an increase in the probability of long-term remission.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_FPn2SNv">Hyperthyroidism and Complications</head><p xml:id="_N8UbuED"><s xml:id="_UBM4qBT">In this analysis, we used the data from randomized controlled trial studies, the NHIS claims data <ref type="bibr" target="#b26">[27]</ref>, and the published literature for determining the probabilities of individuals with hyperthyroidism and its complications from the screening procedure.</s><s xml:id="_SuhJ95e">The primary objective of hyperthyroidism management was to limit the number of major complications, including TAO, heart failure, atrial fibrillation, osteoporosis, fractures, and thyroid cancer.</s><s xml:id="_BUxsa8h">Rates and probabilities of major complications were from a Korean setting were obtained from the NHIS and supplemented with data retrieved from the published literature based on the systematic review.</s><s xml:id="_aaNjkBR">Standard all-cause and disease-specific mortality based on age and risk for South Korea in 2021 <ref type="bibr" target="#b27">[28]</ref> was used in the simulation model.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_PDwFNHq">Quality-of-Life Adjustments and Costs</head><p xml:id="_gq2Md2p"><s xml:id="_y5R9yhZ">Utilities were estimated for all major events, including hyperthyroidism and related complications, which were obtained from published literature based on a systematic review and meta-analysis.</s><s xml:id="_N3ne2tA">Utilities were derived from a patient perspective to provide a more accurate representation of quality-of-life impacts by reflecting patients' lived experiences and to account for adaptation to chronic conditions over time.</s><s xml:id="_V75msaJ">This context-specific approach yields more relevant data for specific treatments, especially for conditions with long-term quality-of-life implications, such as hyperthyroidism or hypothyroidism <ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref>.</s><s xml:id="_WZeQxKb">We adopted a health care system perspective according to the economic evaluation guidelines in Korea <ref type="bibr" target="#b25">[26]</ref>.</s><s xml:id="_u37b243">Direct medical care costs, including physician and hospital reimbursement for treatment procedures, were obtained from the NHIS.</s><s xml:id="_KNs9GeE">Total mean medical care costs for hyperthyroidism, TAO, heart failure, atrial fibrillation, osteoporosis, fractures, and thyroid cancer were obtained and confirmed from the published literature.</s><s xml:id="_822tXDw">Monthly subscription fees for the group with digital monitoring solution use were recurring annually and applied for a lifetime.</s><s xml:id="_uyKRbQ3">Sensitivity analyses were performed to assess the association of cost reduction due to unnecessary hospital visits using the thyroid function digital monitoring solution (70%-100%).</s><s xml:id="_bhBQe76">A 4.5% discount rate was used for both costs and effects in the base-case scenario.</s><s xml:id="_V4d6jgw">Costs were adjusted to the year 2022 using consumer price indices for medical care <ref type="bibr" target="#b32">[33]</ref> and converted to 2022 US dollars (US $1=1293.68</s><s xml:id="_Bd6ZwYV">KRW) <ref type="bibr" target="#b33">[34]</ref>.</s><s xml:id="_zyWmrnF">Table <ref type="table" target="#tab_1">1</ref> presents the quality of life and utility decrements used in the model together with the other parameters.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_3BwZESy">Statistical Analysis</head><p xml:id="_vDusC3m"><s xml:id="_sXAQJhu">Our primary endpoints were QALYs, total costs (2022 USD), and ICERs.</s><s xml:id="_TbVC4a2">Future costs and QALYs were discounted at a rate of 4.5%.</s><s xml:id="_PMxX8NQ">We used a willingness-to-pay (WTP) threshold of US $32,255 per QALY gained, reflecting 1-time the gross domestic product per capita in 2022 South Korea <ref type="bibr" target="#b25">[26,</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref> to determine cost-effectiveness.</s><s xml:id="_kzb4CcE">A strategy was considered preferred if it resulted in the greatest increase in QALYs while being cost-effective.</s><s xml:id="_zraVf57">Overall, this study followed the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) guideline (Checklist 1) <ref type="bibr" target="#b38">[39]</ref>.</s></p><p xml:id="_sQMWpAU"><s xml:id="_ehF6smp">To assess how the uncertainty in model inputs influences the outcomes, we conducted 1-way and probabilistic sensitivity analyses.</s><s xml:id="_H2VBJnR">In 1-way sensitivity analyses, we systematically changed 1 parameter at a time within a specified range of values while keeping all other input variables constant at their base-case values.</s><s xml:id="_e8Q4Hke">The upper and lower bounds for these parameter ranges were determined based on either the minimum and maximum values available in relevant databases or the range of 90%-110% for each value.</s></p><p xml:id="_hVDmWN7"><s xml:id="_jrhPX8S">Probabilistic sensitivity analyses were performed by repeatedly sampling model inputs simultaneously from defined probabilistic distributions.</s><s xml:id="_p29twew">We used gamma distributions for costs and beta distributions for all other parameters.</s><s xml:id="_tGyMGfZ">This process involved running the model 10,000 times, considering a cohort of 10,000 patients.</s><s xml:id="_QbRvxng">We then calculated the percentage of instances in which each strategy was favored under the WTP thresholds.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_5hTQzGD">Ethical Considerations</head><p xml:id="_5RzKvPu"><s xml:id="_7ekr5XD">The procedures of this study underwent expedited review and received approval from the institutional review board of Severance Hospital, Yonsei University (IRB number: 4-2022-1525).</s><s xml:id="_6wNchey">In accordance with local legislation and institutional requirements, ethical approval was not mandatory for this study.</s><s xml:id="_K2EHD7T">Likewise, written informed consent for participation was not required, in accordance with national legislation and institutional requirements.</s><s xml:id="_s25xCQf">All data have been deidentified.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_XmvncB3">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_NbskMHM">Base-Case Analysis</head><p xml:id="_QmQ9fpb"><s xml:id="_bwvHjgS">The results of base-case cost-effectiveness analysis are presented in Table <ref type="table" target="#tab_2">2</ref>. Patients with the implementation of the digital monitoring solution in managing hyperthyroidism were associated with increased costs and increased QALYs.</s><s xml:id="_rDTPWyg">The model predicted that the implementation of digital software in managing hyperthyroidism produced 11.48 QALYs and US $9593 expected costs compared to 11.16 QALYs and US $6445 generated by treatment as usual without digital software aid over a lifetime horizon.</s><s xml:id="_RcSRHYp">The introduction of the thyroid function digital monitoring solution would increase costs by US $3143 and prolong QALYs by 0.32.</s><s xml:id="_BNpar6A">The ICER associated with hyperthyroidism with digital intervention management tool was US $9804.30</s><s xml:id="_McD8frQ">per QALY gained (Table <ref type="table" target="#tab_2">2</ref>), which was well below the hypothetical threshold value in Korea of US $32,255 per QALY gained.</s></p><p xml:id="_ErJrdaW"><s xml:id="_jNmpaBV">Notably, the Markov probability analysis revealed that hyperthyroidism management with digital intervention increased the proportion of long-term remission and reduced the likelihood of postremission relapse of hyperthyroidism (Table <ref type="table" target="#tab_2">2</ref> and Figure <ref type="figure" target="#fig_3">3</ref>).</s><s xml:id="_dgVBkrm">Complications Hypothyroidism Relapse long-term ADT Death Long-term remission With digital software support Stage Probability Complications Hypothyroidism Relapse long-term ADT Death Long-term remission Without digital software support Stage Probability</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_qYvf8Qm">Sensitivity Analysis</head><p xml:id="_9UcfzA3"><s xml:id="_zU4bmk6">We conducted a 1-way deterministic sensitivity analysis.</s><s xml:id="_PRGWDZm">The results of the 1-way deterministic sensitivity analyses with the tornado diagram are shown in Figure <ref type="figure" target="#fig_4">4</ref>.</s><s xml:id="_WmEqswu">The annual cost of the digital monitoring solution use, which ranged from US $120 to US $600, had the largest impact on the ICER value, followed by use of TAO and the sensitivity of the digital software.</s><s xml:id="_VqPgbqW">According to the one-way threshold analysis for the monthly digital support cost, the digital software aid arm became the dominant strategy when the cost was below US $10 per month (Multimedia Appendix 1 and Figure <ref type="figure" target="#fig_2">2</ref>).</s><s xml:id="_dfsn2Ae">Even the highest ICER value observed in this diagram was still below the threshold value of US $32,255 per QALY gained.</s></p><p xml:id="_nWbXhzt"><s xml:id="_RMVJrwE">In Table <ref type="table" target="#tab_3">3</ref>, the ICERs were altered based on the assumption that hospital visits for TFT would decrease as hormone status is monitored and managed.</s><s xml:id="_Xg6h2Zn">This reduction would lead to lower costs associated with unnecessary hospital visits and tests.</s></p><p xml:id="_DvauNgC"><s xml:id="_EsvPYtx">For the Monte Carlo simulations, we presented the results of probabilistic sensitivity analysis as a cost-effectiveness acceptability curve, cost-effectiveness scatter plot, and incremental cost-effectiveness scatterplots.</s><s xml:id="_QEY6Euf">To study the uncertainty in our results, the statistical uncertainty was tested probabilistically 10,000 times.</s><s xml:id="_jHZMCUe">The result of the probabilistic analysis presented as acceptability curves in Figure <ref type="figure" target="#fig_5">5</ref> described the probabilities of being cost-effective when WTP changes.</s><s xml:id="_wguAatq">From the results of the Monte Carlo simulation, the digital intervention was the optimal cost-effective strategy with a probability of 64.4% represented in the form of an ICE scatterplot in Figure <ref type="figure" target="#fig_5">5</ref>.   Willingness to pay With digital software support Without digital software support Incremental effectiveness Incremental cost %iterations cost-effectiveness</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_FPsMAsx">Discussion</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_mpSMbGF">Principal Findings</head><p xml:id="_WYNmwuv"><s xml:id="_DHHf9ze">The application of artificial intelligence-driven wearable devices in cardiac disease management is operative; however, there is little evidence of their applications in thyroid disease and its cost-effectiveness.</s><s xml:id="_2EMKtbN">To the best of our knowledge, this is the first economic evaluation that considers the cost-effectiveness of a wearable or mobile-based thyroid function digital monitoring solution compared with standard care from a health care system perspective.</s><s xml:id="_XxRNmgT">The results demonstrated that this digital monitoring support would provide an incremental health gain per patient of 0.32 QALY with an ICER of US $9804.30</s><s xml:id="_7GSPaDU">per QALY gained.</s><s xml:id="_j6cr8xU">A Markov microsimulation model was developed to optimize the use of data from the published studies based on a systematic review while accounting for the diversity and variability among patients with hyperthyroidism.</s><s xml:id="_fYPfFt3">The findings indicated that aiding patients with the digital monitoring solution resulted in slightly increased health care costs and improved health benefits compared to standard care.</s><s xml:id="_Xa227w7">Therefore, the digital solution was considered highly cost-effective for functional outcomes in hyperthyroid management using a WTP threshold of US $32,255 per QALY gained.</s></p><p xml:id="_CtMNSyH"><s xml:id="_AkSsMMp">Both deterministic and probabilistic sensitivity analyses demonstrated the robustness of our results.</s><s xml:id="_UwsQdyJ">The cost-effectiveness was sensitive to the annual subscription fee for the hyperthyroidism management platform use, use of TAO, sensitivity of the digital device, initial treatment cost of hyperthyroidism, and use of long-term ATD.</s><s xml:id="_PAwtXsp">Despite these sensitivities, the digital intervention strategy maintained its advantageous position by including most of the parameters, with an ICER remaining below the threshold of US $32,255.</s></p><p xml:id="_fkdn8fs"><s xml:id="_wFeZjJb">Our analysis revealed that the monthly cost of a digital monitoring solution for hyperthyroidism had the greatest impact on ICERs in the 1-way deterministic sensitivity analysis.</s><s xml:id="_NxfKsTM">Although the model inputs and target disease were different, other studies pointed out a similar conclusion by evaluating the cost-effectiveness of digital therapeutics for low back pain <ref type="bibr" target="#b39">[40]</ref> and hypertension <ref type="bibr" target="#b40">[41]</ref>.</s><s xml:id="_Wbnj2Ve">The result from our model indicates that even minor adjustments in pricing can shift the balance between different strategies in this particular scenario, highlighting the sensitivity of the economic implications of these digital tools to various factors such as implementation details, settings, payer viewpoints, and assumed unnecessary hospital visit reduction.</s><s xml:id="_sRt7s5u">Further research exploring diverse payment approaches for digital intervention will be essential for conducting robust comparisons and reaching definitive conclusions regarding the health economic outcomes linked to digital technology.</s><s xml:id="_F3MKefg">In Korea's single-payer system, the adoption of artificial intelligence-based systems is significantly influenced by the rate at which reimbursements are provided.</s></p><p xml:id="_uv59tke"><s xml:id="_BpkEhXG">The major drawback of ATD therapy is the high recurrence rate of GD, the most common cause of hyperthyroidism, ranging from 20% to 70%, once the conventional 12-18 months of treatment is discontinued <ref type="bibr" target="#b41">[42]</ref>.</s><s xml:id="_RzTnGZa">The serum concentration of thyrotropin receptor antibodies, a significant predictor of relapse in GD, can fluctuate or remain elevated in patients with GD, regardless of the continuous use of ATD.</s><s xml:id="_6jDUvVR">Therefore, there is a higher incidence of GD recurrence in clinical remission states following ATD treatment.</s><s xml:id="_7sYSAgn">The median duration of remission after ATD treatment is reported to be approximately 6.8 years <ref type="bibr" target="#b42">[43]</ref>, leading to suggestions of continuous, long-term ATD therapy <ref type="bibr" target="#b43">[44]</ref><ref type="bibr" target="#b44">[45]</ref><ref type="bibr" target="#b45">[46]</ref><ref type="bibr" target="#b46">[47]</ref>.</s><s xml:id="_ZJmwPRc">A meta-analysis has shown that for each additional year of ATD treatment beyond 24 months, the remission rate increases by 16% <ref type="bibr" target="#b47">[48]</ref>.</s><s xml:id="_Te7cX4H">These findings suggest that in cases where thyrotropin receptor antibody levels fail to return to normal after the conventional 12-18 months of ATD treatment, the possibility of considering long-term therapy should be explored <ref type="bibr" target="#b48">[49]</ref>.</s><s xml:id="_KezVXvd">Therefore, international medical societies are now considering long-term treatment as an option for managing Graves hyperthyroidism <ref type="bibr" target="#b41">[42,</ref><ref type="bibr" target="#b49">50]</ref>.</s></p><p xml:id="_BX2xbs7"><s xml:id="_FxjrW2a">Significant adherence to pharmacological treatments is a multifaceted behavior influenced by various factors at different stages of a person's medication journey.</s><s xml:id="_3DmfRea">Adherence to long-term therapy for chronic illnesses is estimated to reach only 50% on average <ref type="bibr" target="#b50">[51]</ref>.</s><s xml:id="_Z7aQA55">At present, no single intervention has proven consistently effective in addressing long-term nonadherence.</s><s xml:id="_TfEXqqg">Digital interventions for medication adherence, however, offer a potential solution to enhance adherence by providing multifaceted interventions tailored to individual needs.</s><s xml:id="_PDWZ6GM">Digital technological interventions have displayed initial promise in boosting medication adherence rates and offering health care professionals the ability to monitor and assess adherence <ref type="bibr" target="#b51">[52]</ref><ref type="bibr" target="#b52">[53]</ref><ref type="bibr" target="#b53">[54]</ref><ref type="bibr" target="#b54">[55]</ref>.</s><s xml:id="_bTm8uWm">Effectively managing hyperthyroidism requires patients to integrate it into their daily lives.</s><s xml:id="_8Ep32n3">By integrating digital monitoring solutions into the management of thyroid dysfunction, patients can regularly check their thyroid function status as part of their daily life, ensuring adherence to their medication schedule and promoting long-term health outcomes improvement.</s></p><p xml:id="_8j7wGkF"><s xml:id="_3crg4Hx">In this research, we demonstrated the implementation of a digital intervention aid specifically designed to aid in the management of patients with hyperthyroidism.</s><s xml:id="_RvtBNNm">This innovation holds the potential to enhance health care outcomes and deliver cost-effectiveness on a large scale.</s><s xml:id="_WEEyM6G">Our sensitivity analyses have highlighted the robustness of our findings, even when considering variations in model parameters and assumptions.</s><s xml:id="_wsVJpbF">It is important to note that our study primarily adopts the perspective of the Korean national health care system and does not encompass a broader view of societal costs.</s><s xml:id="_FRFD9Uz">Given the fact that hyperthyroidism is prevalent among individuals younger than 65 years, it is conceivable that the cost-effectiveness associated with hyperthyroidism could be even more substantial if we were to take into account factors such as productivity losses and a wider range of societal costs <ref type="bibr" target="#b11">[12]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_HdzQtUM">Limitations</head><p xml:id="_5nvRmJq"><s xml:id="_4krENgU">This study comes with several limitations.</s><s xml:id="_eBdJJh8">We applied patient-derived uses in the study.</s><s xml:id="_8Syt5rB">Patients may underestimate the severity of certain health states due to adaptation or limited awareness of alternative health states, which can lead to higher-than-expected utility values.</s><s xml:id="_Rr8sJH5">This effect is especially relevant in chronic conditions, where patients may grow accustomed to their symptoms over time; however, we adjusted these values by applying a decrement.</s><s xml:id="_t8J7vZU">While our analysis focused on the perspective of health care providers, it is essential to recognize that thyroid dysfunction has substantial health-related and economic implications not only for individual patients but also for society as a whole.</s><s xml:id="_TEgFkZA">The broader societal costs are expected to increase in the future, primarily due to the population with hyperthyroidism being an active working-age population in the society.</s><s xml:id="_Vda4eEn">In addition, because digital intervention-supported management has not been systematically integrated into health care practice in Korea and due to uncertainties surrounding the application of digital health frameworks, there remain ambiguities related to our estimates.</s><s xml:id="_CBz2xPm">Moreover, uncertainties are compounded by the possibility of negotiations influencing unit prices, which contribute to the overall expenses of the digital-based platform, especially if the intervention were to be introduced.</s><s xml:id="_MyMXfcP">We did not apply attrition rates in the model as we assumed that the patient with digital intervention would keep using the tool to manage hyperthyroidism, which could impact lifetime ICER.</s><s xml:id="_NMfGfQP">In addition, a limitation of this study is the potential discomfort associated with wearable or mobile-based monitoring solutions, particularly the burden of continuous use.</s><s xml:id="_ccU4aQu">This is especially relevant to older adult populations, who may face challenges with digital interventions, potentially adding a societal burden.</s><s xml:id="_DPEQsJq">Although capturing this discomfort in terms of costs or utility values is challenging, it may impact cost-effectiveness by affecting adherence and patient satisfaction.</s><s xml:id="_vN6JG9M">Future research should consider these factors, as they could influence the overall effectiveness and acceptability of digital health interventions.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_nbMKe6s">Conclusions</head><p xml:id="_hyg6mTN"><s xml:id="_qB475u4">In conclusion, the integration of a wearable or mobilebased thyroid function digital monitoring solution demonstrated good cost-effectiveness in hyperthyroidism management compared to ATD treatment as usual.</s><s xml:id="_6m36EXf">Digital monitoring solution cost and its sensitivity influence cost-effectiveness, and we need to explore the balance among the digital monitoring support application cost, accuracy of hormonal level change status, and effectiveness for target patients with hyperthyroidism in clinical practice.</s><s xml:id="_sQtwEp7">Digital therapeutics are currently in a pretest period to determine the extent of reimbursement they may receive from Korea's national universal health insurance system.</s><s xml:id="_cWT9W8M">Therefore, evaluating the cost-effectiveness of digital interventions, as illustrated in this study, is gaining significance in establishing suitable pricing for value-based reimbursement.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p xml:id="_SryBEYs"><s xml:id="_ExNf2Js">Figure1.</s><s xml:id="_TzQCSRP">Description of a wearable or mobile-based thyroid function digital monitoring solution designed for the effective management of hyperthyroidism.</s><s xml:id="_mdVkv8b">(A) Heart rates collected from a wearable device on each date (the date of referred thyroid function test and target date), and (B) the risk level of hyperthyroidism calculated for the target date is determined by comparing the heart rate distribution over N days, including the target date, with the heart rate distribution over N days, including the day of the referred thyroid function test.</s><s xml:id="_bFABRdd">In cases where the risk level surpasses the designated threshold, a notification is sent to the user, prompting them to seek medical attention.</s><s xml:id="_e7hRSfx">TFT: thyroid function test.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 2 .</head><label>2</label><figDesc><div><p xml:id="_tq9j3CT"><s xml:id="_THss4WS">Figure 2. A basic description of the structure in the decision analytic Markov model.</s><s xml:id="_pYXPdFu">ATD: antithyroid drug; RAl: radioactive iodine.</s></p></div></figDesc><graphic coords="4,43.20,16.11,574.95,350.41" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 3 .</head><label>3</label><figDesc><div><p xml:id="_Kgtx6M9"><s xml:id="_ZywXTTk">Figure 3. Markov probability analysis of each state with and without digital software support.</s><s xml:id="_CgkFsTS">ADT: antithyroid drug therapy.</s></p></div></figDesc><graphic coords="7,298.69,258.34,235.65,164.20" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 4 .</head><label>4</label><figDesc><div><p xml:id="_aPECFX4"><s xml:id="_3nxFzpb">Figure 4. Tornado diagram for incremental cost-effectiveness ratio.</s><s xml:id="_jxmuBHm">ADT: antithyroid drug therapy; ICER: incremental cost-effectiveness ratio; TAO: thyroid-associated orbitopathy; WTP: willingness to pay.</s></p></div></figDesc><graphic coords="8,43.15,95.76,437.58,186.94" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 5 .</head><label>5</label><figDesc><div><p xml:id="_KctyMNp"><s xml:id="_gF2W2A8">Figure 5. Results of probabilistic sensitivity analysis: (A) cost-effectiveness acceptability curve and (B) incremental cost-effectiveness scatterplot.</s><s xml:id="_cDTT6es">WTP: willingness to pay.A B</s></p></div></figDesc><graphic coords="8,310.18,555.08,243.29,184.36" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc><div><p xml:id="_TQ6YV5t"><s xml:id="_QTg3UBT">Base</s></p></div></figDesc><table><row><cell>Atrial fibrillation Heart failure Osteoporosis Fracture Thyroid cancer Hyperthyroidism sensitivity Hyperthyroidism specificity T4 c + TSH d sensitivity T4 + TSH specificity QALYs e , estimate (range) Thyroid cancer Hypothyroid Thyroid-associated orbitopathy Hyperthyroidism with ATD</cell><cell>4.3% (range 3%-5%) 1.6% (range 1.1%-2.1%) 1.59% (range 1.09%-2.09%) 3.3% (range 2.8%-3.8%) 1.23% (range 0.9%-2%) 87.13 (range 78.4-95.8) 83.78 (range 75.4-92.15) 100 100 0.897 (0.852-0.941) 0.9479 (0.902-0.997) 0.84 (0.798-0.882) 0.86 (t0.817-0.903)</cell><cell>Beta Beta Beta Beta Beta Beta Beta Uniform Uniform Beta Beta Beta Beta</cell><cell>NHIS b [17], NHIS NHIS NHIS [18] GlandyTM, THYROSCOPE INC GlandyTM [19], Assumption [19], Assumption [20] [21] [22] [23]</cell></row></table><note xml:id="_5Xz8kaw"><p>case values and references of model input parameters.</p><p>Parameter Estimation Distribution Source</p><p>Prevalence of hyperthyroidism 7.20% (range 5.76%-8.64%) Beta<ref type="bibr" target="#b11">[12]</ref> </p><p>Failure of ATD a 5% (range 4%-6%) over 1.5 years Beta<ref type="bibr" target="#b12">[13]</ref> </p><p>Hypothyroidism 2.9% (range 2.32%-3.48%) over 10.2 years Beta<ref type="bibr" target="#b13">[14]</ref> </p><p>Relapse postremission with ATD 52.8% (range 42.24%-63.36%) over 3.73 years (reverts to 0 after 5 years) Beta<ref type="bibr" target="#b14">[15]</ref> </p><p>Thyroid-associated orbitopathy 25% (range 20%-30%) Beta<ref type="bibr" target="#b15">[16]</ref> </p><p>a ATD: antithyroid drug. b NHIS: National Health Insurance Service. c T4: thyroxine. d TSH: thyroid-stimulating hormone.</p><p><s xml:id="_NuRQxjN">e QALY: quality-adjusted life year.</s><s xml:id="_MDY5QPk">f ADT: antithyroid drug therapy.</s><s xml:id="_dd6adQZ">g KRW: Korean won.</s><s xml:id="_frXp4Wd">h Not applicable.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 .</head><label>2</label><figDesc><div><p xml:id="_BqWznhW"><s xml:id="_K5sMBwD">Effectiveness and cost estimates for two strategies on a simulated cohort of patients with hyperthyroidism.</s></p></div></figDesc><table><row><cell>Hyperthyroidism managed without digital software support</cell><cell>Hyperthyroidism managed with digital software support</cell></row><row><cell>Long-term remission, % (n/N) 17.48 (748/10,000) Complications, % (n/N) 15.17 (1517/10,000) Hypothyroidism, % (n/N) 5.40 (540/10,000) Relapse postremission with 26.37 (2637/10,000) ATD a , % (n/N) Discounted lifetime cost per 6449.77 person, US $ Discounted incremental cost -per person, US $ Discounted lifetime 11.16 effectiveness per person, QALY b Discounted incremental QALY effectiveness per person, -</cell><cell>22.68 (2268/10,000) 18.84 (1884/10,000) 5.02 (502/10,000) 17.87 (1787/10,000) 9592.55 3142.78 11.48 0.32</cell></row></table><note xml:id="_dtRatp7"><p><s xml:id="_hQqFUDc">a ATD: antithyroid drug.</s><s xml:id="_g3nYctj">b QALY: quality-adjusted life year.</s><s xml:id="_Kzdwrpq">c ICER: incremental cost-effectiveness ratio.</s><s xml:id="_pvzPdTR">d NMB: net monetary benefit.</s><s xml:id="_jCjbjDF">e WTP: willingness to pay.</s><s xml:id="_KfSrvff">f INMB: incremental net monetary benefit.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3 .</head><label>3</label><figDesc><div><p xml:id="_yEd37eX"><s xml:id="_S7kRDNT">One-way sensitivity analysis by reduction of cost for hospital visits.</s></p></div></figDesc><table><row><cell>Strategy</cell><cell>Cost (US $)</cell><cell>QALY a (years)</cell><cell>ICER b ($ per QALY)</cell></row><row><cell cols="2">Base case Treatment as usual Management with digital aid 10% cost reduction from unnecessary hospital visits 6449.77 9592.56 Treatment as usual 6449.77 Management with digital aid 9541.50 20% cost reduction from unnecessary hospital visits Treatment as usual 6449.77 Management with digital aid 9490.45 30% cost reduction from unnecessary hospital visits Treatment as usual 6449.77 Management with digital aid 9439.39</cell><cell>11.16 11.48 11.16 11.48 11.16 11.48 11.16 11.48</cell><cell>-9804.31 -9654.04 -9485.76 -9326.48</cell></row></table><note xml:id="_kKuw4Gc"><p><s xml:id="_SRzJJD5">a QALY: quality-adjusted life year.</s><s xml:id="_5WXTxCD">b ICER: incremental cost-effectiveness ratio.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_dab6hNB"><s xml:id="_uvHFkq6">https://mhealth.jmir.org/2025/1/e56738</s><s xml:id="_rEmaRY7">JMIR Mhealth Uhealth 2025 | vol.</s><s xml:id="_2Sfxmtj">13 | e56738 | p. 2 (page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1"><p xml:id="_FX42pMC"><s xml:id="_JU5QpkR">https://mhealth.jmir.org/2025/1/e56738</s><s xml:id="_Z3vAS3m">JMIR Mhealth Uhealth 2025 | vol.</s><s xml:id="_Ch5JEnb">13 | e56738 | p. 3 (page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_2"><p xml:id="_VSUtz3H"><s xml:id="_puSZ9fM">https://mhealth.jmir.org/2025/1/e56738</s><s xml:id="_pXFTcx2">JMIR Mhealth Uhealth 2025 | vol.</s><s xml:id="_ZFNUMpj">13 | e56738 | p. 4 (page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_3"><p xml:id="_AuSCW7S"><s xml:id="_PrMzURH">https://mhealth.jmir.org/2025/1/e56738</s><s xml:id="_pFN66Xz">JMIR Mhealth Uhealth 2025 | vol.</s><s xml:id="_9caYKwj">13 | e56738 | p. 5 (page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_4"><p xml:id="_guffD5j"><s xml:id="_Xb8msGn">https://mhealth.jmir.org/2025/1/e56738</s><s xml:id="_etbMGAz">JMIR Mhealth Uhealth 2025 | vol.</s><s xml:id="_SE8U2Ya">13 | e56738 | p. 6 (page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_5"><p xml:id="_EUJGhmT"><s xml:id="_rVpFQSz">https://mhealth.jmir.org/2025/1/e56738</s><s xml:id="_WhP9kn3">JMIR Mhealth Uhealth 2025 | vol.</s><s xml:id="_jzVw3MX">13 | e56738 | p. 7 (page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_6"><p xml:id="_Xm3GVRy"><s xml:id="_APxWBHU">https://mhealth.jmir.org/2025/1/e56738</s><s xml:id="_CdRxFsK">JMIR Mhealth Uhealth 2025 | vol.</s><s xml:id="_Tb6Fhqd">13 | e56738 | p. 8 (page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_7"><p xml:id="_tKq95Qu"><s xml:id="_KmDFafc">https://mhealth.jmir.org/2025/1/e56738</s><s xml:id="_r9pQgZH">JMIR Mhealth Uhealth 2025 | vol.</s><s xml:id="_q9DFq5x">13 | e56738 | p. 9 (page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_8"><p xml:id="_96bbZC6"><s xml:id="_c73pDAT">https://mhealth.jmir.org/2025/1/e56738</s><s xml:id="_cXfgKN3">JMIR Mhealth Uhealth 2025 | vol.</s><s xml:id="_m3VCXjw">13 | e56738 | p. 10 (page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_9"><p xml:id="_596jzgK"><s xml:id="_Q48Rhkj">https://mhealth.jmir.org/2025/1/e56738</s><s xml:id="_Tz9tXUW">JMIR Mhealth Uhealth 2025 | vol.</s><s xml:id="_2TrG5cw">13 | e56738 | p. 11 (page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_10"><p xml:id="_C9u4fPe"><s xml:id="_xNbjK7f">https://mhealth.jmir.org/2025/1/e56738</s><s xml:id="_EKfYu59">JMIR Mhealth Uhealth 2025 | vol.</s><s xml:id="_cJNGyHS">13 | e56738 | p. 12 (page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_11"><p xml:id="_waEAUhp"><s xml:id="_aFRfAsp">https://mhealth.jmir.org/2025/1/e56738</s><s xml:id="_skXD4N4">JMIR Mhealth Uhealth 2025 | vol.</s><s xml:id="_DNbCnqx">13 | e56738 | p. 13 (page number not for citation purposes)</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head xml:id="_2mCQtQr">Acknowledgments</head><p xml:id="_kQRRysB"><s xml:id="_PGAUuQu">This work was supported by the <rs type="funder">Hankuk University of Foreign Studies Research Fund</rs>.</s><s xml:id="_JFKGNTZ">It is also supported by the <rs type="programName">Technological Innovation R and D Program</rs> (<rs type="grantNumber">RS-2023-00281098</rs>) funded by the <rs type="funder">Ministry of SMEs and Startups (MSS, Korea)</rs>.</s><s xml:id="_gTTm3p7">In addition, this research was supported by the AI-based <rs type="programName">Medical System Digital Transformation Support Program</rs> through the <rs type="funder">National IT Industry Promotion Agency (NIPA)</rs>, funded by the <rs type="funder">Ministry of Science and ICT</rs> (<rs type="grantNumber">H0906-24-1006</rs>).</s><s xml:id="_dhh2sZw">A grant from the <rs type="funder">Korean Thyroid Association Clinical Research Award</rs> (2019) also contributed to this work.</s><s xml:id="_kRWK8nc">We express our gratitude to <rs type="institution">THYROSCOPE INC</rs> for providing information regarding digital intervention management for hyperthyroidism, which was critical to this study.</s></p></div>
			</div>
			<div type="funding">
<div xml:id="_pFzYjxJ"><p xml:id="_H7ygTJ4"><s xml:id="_NDNk2xN">Annual subscription fee (120 to 600) Use of TAO (0.882 to 0.798) Sensitivity of digital software (0.958 to 0.798) Cost of the initial year of hyperthyroidism (1194.93 to 977.67) Use of hyperthyroidism with ADT (0.817 to 0.903) Probability of remission (0.176 to 0.144) Probability of ophthalmology (0.2 to 0.3) Cost of long-term remission (259.25 to 316.87) Probability of relapse long-term ADT (0.133 to 0.156) Use of hypothyroidism (0.623 to 0.761) 32,<rs type="grantNumber">255 WTP: 32</rs>,<rs type="grantNumber">255</rs></s></p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_PqbpBwt">
					<idno type="grant-number">RS-2023-00281098</idno>
					<orgName type="program" subtype="full">Technological Innovation R and D Program</orgName>
				</org>
				<org type="funding" xml:id="_H8VbsB9">
					<orgName type="program" subtype="full">Medical System Digital Transformation Support Program</orgName>
				</org>
				<org type="funding" xml:id="_nwsv8U4">
					<idno type="grant-number">H0906-24-1006</idno>
				</org>
				<org type="funding" xml:id="_GfEjfej">
					<idno type="grant-number">255 WTP: 32</idno>
				</org>
				<org type="funding" xml:id="_ud9tZh7">
					<idno type="grant-number">255</idno>
				</org>
			</listOrg>

			<div type="availability">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Nj9k8jh">Data Availability</head><p xml:id="_6HTf2aB"><s xml:id="_4jAyJjA">The datasets generated or analyzed during this study are available from the corresponding author on reasonable request.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_b5YgGZF">Authors' Contributions</head><p xml:id="_ttkR4Je"><s xml:id="_d32GWNX">JHK had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</s><s xml:id="_CSEhbMw">JHM contributed clinical expertise to interpret the results and assisted with manuscript writing, with a focus on minimizing potential conflicts of interest in data analysis and result interpretation.</s><s xml:id="_mWA22NB">JHK and JHM contributed equally as cocorresponding authors.</s><s xml:id="_wfvJg3G">JHK, JS, and JHM conceived and designed the study.</s><s xml:id="_uZEKJfG">JHK compiled the data and conducted the analyses.</s><s xml:id="_QcSKHd5">JHK and MSK developed the decision tree and Markov model.</s><s xml:id="_4APfHEJ">JHK and JHM drafted the manuscript.</s><s xml:id="_FVvEx67">JHK, JS, MSK, and JHM critically revised the manuscript for important intellectual content.</s><s xml:id="_ePwZxQn">JHK and JHM contributed equally as corresponding authors.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_yrc7Pu8">Conflicts of Interest</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_Aqeeb3C">Graves&apos; Disease</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hegeds</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejmra1510030</idno>
		<idno>Medline: 27797318</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Fb8EmG2">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="issue">16</biblScope>
			<biblScope unit="page" from="1552" to="1565" />
			<date type="published" when="2016-10-20">Oct 20. 2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Smith TJ, Hegeds L. Graves&apos; Disease. N Engl J Med. Oct 20, 2016;375(16):1552-1565. [doi: 10.1056/ NEJMra1510030] [Medline: 27797318]</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_dEqDgUq">Prevalence, treatment status, and comorbidities of hyperthyroidism in Korea from 2003 to 2018: a nationwide population study</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Ahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Lee</surname></persName>
		</author>
		<idno type="DOI">10.3803/enm.2023.1684</idno>
		<idno>Medline: 37435663</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WfwHaGr">Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="436" to="444" />
			<date type="published" when="2023-08">Aug 2023</date>
			<pubPlace>Seoul)</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Ahn HY, Cho SW, Lee MY, et al. Prevalence, treatment status, and comorbidities of hyperthyroidism in Korea from 2003 to 2018: a nationwide population study. Endocrinol Metab (Seoul). Aug 2023;38(4):436-444. [doi: 10.3803/EnM. 2023.1684] [Medline: 37435663]</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_NrZSt7q">Hyperthyroidism and thyrotoxicosis</title>
		<author>
			<persName><forename type="first">D</forename><surname>Devereaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Z</forename><surname>Tewelde</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.emc.2013.12.001</idno>
		<idno>Medline: 24766932</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vJX536w">Emerg Med Clin North Am</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="277" to="292" />
			<date type="published" when="2014-05">May 2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Devereaux D, Tewelde SZ. Hyperthyroidism and thyrotoxicosis. Emerg Med Clin North Am. May 2014;32(2):277-292. [doi: 10.1016/j.emc.2013.12.001] [Medline: 24766932]</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_CUnZ5YQ">Wearable photoplethysmographic sensors-past and present</title>
		<author>
			<persName><forename type="first">T</forename><surname>Tamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Maeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sekine</surname></persName>
		</author>
		<idno type="DOI">10.3390/electronics3020282</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_K2tv7UH">Electronics</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="282" to="302" />
			<date type="published" when="2014">2014</date>
			<pubPlace>Basel)</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Tamura T, Maeda Y, Sekine M, et al. Wearable photoplethysmographic sensors-past and present. Electronics (Basel). 2014;3(2):282-302. [doi: 10.3390/electronics3020282]</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_Q9TKwss">Human photoplethysmogram: new insight into chaotic characteristics</title>
		<author>
			<persName><forename type="first">N</forename><surname>Sviridova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sakai</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.chaos.2015.05.005</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_azD8H6d">Chaos, Solitons &amp; Fractals</title>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="page" from="53" to="63" />
			<date type="published" when="2015-08">Aug 2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sviridova N, Sakai K. Human photoplethysmogram: new insight into chaotic characteristics. Chaos, Solitons &amp; Fractals. Aug 2015;77:53-63. [doi: 10.1016/j.chaos.2015.05.005]</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_AFsYuQf">Estimating accuracy at exercise intensities: a comparative study of selfmonitoring heart rate and physical activity wearable devices</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Dooley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Golaszewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Bartholomew</surname></persName>
		</author>
		<idno type="DOI">10.2196/mhealth.7043</idno>
		<idno>Medline: 28302596</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rdCgpPJ">JMIR Mhealth Uhealth</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">34</biblScope>
			<date type="published" when="2017-03-16">Mar 16, 2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dooley EE, Golaszewski NM, Bartholomew JB. Estimating accuracy at exercise intensities: a comparative study of self- monitoring heart rate and physical activity wearable devices. JMIR Mhealth Uhealth. Mar 16, 2017;5(3):e34. [doi: 10. 2196/mhealth.7043] [Medline: 28302596]</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_X6dmAt7">Accuracy of wrist-worn heart rate monitors</title>
		<author>
			<persName><forename type="first">R</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Blackburn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Desai</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamacardio.2016.3340</idno>
		<idno>Medline: 27732703</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fPeTJrf">JAMA Cardiol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="104" to="106" />
			<date type="published" when="2017-01-01">Jan 1, 2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wang R, Blackburn G, Desai M, et al. Accuracy of wrist-worn heart rate monitors. JAMA Cardiol. Jan 1, 2017;2(1):104-106. [doi: 10.1001/jamacardio.2016.3340] [Medline: 27732703]</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_fjfy5s5">Clinical feasibility of monitoring resting heart rate using a wearable activity tracker in patients with thyrotoxicosis: prospective longitudinal observational study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Oh</surname></persName>
		</author>
		<idno type="DOI">10.2196/mhealth.9884</idno>
		<idno>Medline: 30006328</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3PguTQn">JMIR Mhealth Uhealth</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page">e159</biblScope>
			<date type="published" when="2018-07-13">Jul 13, 2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lee JE, Lee DH, Oh TJ, et al. Clinical feasibility of monitoring resting heart rate using a wearable activity tracker in patients with thyrotoxicosis: prospective longitudinal observational study. JMIR Mhealth Uhealth. Jul 13, 2018;6(7):e159. [doi: 10.2196/mhealth.9884] [Medline: 30006328]</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_BEgcdQf">Association between thyroid function and heart rate monitored by wearable devices in patients with hypothyroidism</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Ahn</surname></persName>
		</author>
		<idno type="DOI">10.3803/EnM.2021.1216</idno>
		<idno>Medline: 34674500</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xX8Jj2r">Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1121" to="1130" />
			<date type="published" when="2021-10">Oct 2021</date>
			<pubPlace>Seoul)</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Kim KH, Lee J, Ahn CH, et al. Association between thyroid function and heart rate monitored by wearable devices in patients with hypothyroidism. Endocrinol Metab (Seoul). Oct 2021;36(5):1121-1130. [doi: 10.3803/EnM.2021.1216] [Medline: 34674500]</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_x3YHS7Y">The diagnosis and management of hyperthyroidism in Korea: consensus report of the Korean Thyroid Association</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Moon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Yi</surname></persName>
		</author>
		<idno type="DOI">10.3803/EnM.2013.28.4.275</idno>
		<idno>Medline: 24396691</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BmaG3xY">Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="275" to="279" />
			<date type="published" when="2013-12">Dec 2013</date>
			<pubPlace>Seoul)</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Moon JH, Yi KH. The diagnosis and management of hyperthyroidism in Korea: consensus report of the Korean Thyroid Association. Endocrinol Metab (Seoul). Dec 2013;28(4):275-279. [doi: 10.3803/EnM.2013.28.4.275] [Medline: 24396691]</note>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Drummond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Sculpher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Claxton</surname></persName>
		</author>
		<idno type="DOI">10.1093/oso/9780198529446.003.0002</idno>
		<title level="m" xml:id="_pxwhspR">Methods for the Economic Evaluation of Health Care Programmes</title>
		<imprint>
			<publisher>Oxford University Press</publisher>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press; 2015.</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_aMenqUk">Incidence &amp; prevalence of hyperthyroidism and preference for therapeutic modalities in Korea</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Seo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Chung</surname></persName>
		</author>
		<idno type="DOI">10.11106/jkta.2013.6.1.56</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_PEHgFTJ">J Korean Thyroid Assoc</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">56</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Seo GH, Kim SW, Chung JH. Incidence &amp; prevalence of hyperthyroidism and preference for therapeutic modalities in Korea. J Korean Thyroid Assoc. 2013;6(1):56. [doi: 10.11106/jkta.2013.6.1.56]</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_haa3UHZ">Treatment options for Graves disease: a cost-effectiveness analysis</title>
		<author>
			<persName><forename type="first">H</forename><surname>In</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">N</forename><surname>Pearce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Wong</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jamcollsurg.2009.03.025</idno>
		<idno>Medline: 19632593</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4GhbrFg">J Am Coll Surg</title>
		<imprint>
			<biblScope unit="volume">209</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="170" to="179" />
			<date type="published" when="2009-08">Aug 2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">In H, Pearce EN, Wong AK, et al. Treatment options for Graves disease: a cost-effectiveness analysis. J Am Coll Surg. Aug 2009;209(2):170-179. [doi: 10.1016/j.jamcollsurg.2009.03.025] [Medline: 19632593]</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_JADfHJ3">Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine</title>
		<author>
			<persName><forename type="first">F</forename><surname>Azizi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ataie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hedayati</surname></persName>
		</author>
		<idno type="DOI">10.1530/eje.1.01904</idno>
		<idno>Medline: 15879354</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_YvvCBz2">Eur J Endocrinol</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="695" to="701" />
			<date type="published" when="2005-05">May 2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Azizi F, Ataie L, Hedayati M, et al. Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur J Endocrinol. May 2005;152(5):695-701. [doi: 10.1530/eje.1.01904] [Medline: 15879354]</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_Za4hAtV">Comparative effectiveness of therapies for Graves&apos; hyperthyroidism: a systematic review and network meta-analysis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Sundaresh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Brito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1210/jc.2013-1954</idno>
		<idno>Medline: 23824415</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3KWKHkC">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="3671" to="3677" />
			<date type="published" when="2013-09">Sep 2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sundaresh V, Brito JP, Wang Z, et al. Comparative effectiveness of therapies for Graves&apos; hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. Sep 2013;98(9):3671-3677. [doi: 10.1210/jc.2013-1954] [Medline: 23824415]</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_JcJhXkn">Current knowledge on Graves&apos; orbitopathy</title>
		<author>
			<persName><forename type="first">K</forename><surname>Gontarz-Nowak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Szychliska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Matuszewski</surname></persName>
		</author>
		<idno type="DOI">10.3390/jcm10010016</idno>
		<idno>Medline: 33374706</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xmqygqN">J Clin Med</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">16</biblScope>
			<date type="published" when="2020-12-23">Dec 23. 2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gontarz-Nowak K, Szychliska M, Matuszewski W, et al. Current knowledge on Graves&apos; orbitopathy. J Clin Med. Dec 23, 2020;10(1):16. [doi: 10.3390/jcm10010016] [Medline: 33374706]</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_crngx6s">Thyroid function and mortality in patients treated for hyperthyroidism</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Franklyn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Sheppard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Maisonneuve</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.294.1.71</idno>
		<idno>Medline: 15998893</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GmfgaXx">JAMA. Jul</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="71" to="80" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA. Jul 6, 2005;294(1):71-80. [doi: 10.1001/jama.294.1.71] [Medline: 15998893]</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_zyrwXrU">Hyperthyroidism and thyroid cancer risk: a population-based cohort study</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Yeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Chou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Weng</surname></persName>
		</author>
		<idno type="DOI">10.1055/s-0033-1341474</idno>
		<idno>Medline: 23616188</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Zr9S8hU">Exp Clin Endocrinol Diabetes</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="402" to="406" />
			<date type="published" when="2013-07">Jul 2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Yeh NC, Chou CW, Weng SF, et al. Hyperthyroidism and thyroid cancer risk: a population-based cohort study. Exp Clin Endocrinol Diabetes. Jul 2013;121(7):402-406. [doi: 10.1055/s-0033-1341474] [Medline: 23616188]</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_gErY6EG">Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>De Los Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Starich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Mazzaferri</surname></persName>
		</author>
		<idno type="DOI">10.1001/archinte.1989.00390030032006</idno>
		<idno>Medline: 2493228</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_37pNESw">Arch Intern Med. Mar</title>
		<imprint>
			<biblScope unit="volume">149</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="526" to="532" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
	<note type="raw_reference">de los Santos ET, Starich GH, Mazzaferri EL. Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients. Arch Intern Med. Mar 1989;149(3):526-532. [doi: 10. 1001/archinte.149.3.526] [Medline: 2493228]</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_mcfDuKy">Age-related differences in health-related quality of life among thyroid cancer survivors compared with a normative sample: results from the PROFILES Registry</title>
		<author>
			<persName><forename type="first">F</forename><surname>Mols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schoormans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jwa</forename><surname>Smit</surname></persName>
		</author>
		<idno type="DOI">10.1002/hed.25325</idno>
		<idno>Medline: 29756245</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_tuV2JP9">Head Neck</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="2235" to="2245" />
			<date type="published" when="2018-10">Oct 2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mols F, Schoormans D, Smit JWA, et al. Age-related differences in health-related quality of life among thyroid cancer survivors compared with a normative sample: results from the PROFILES Registry. Head Neck. Oct 2018;40(10):2235-2245. [doi: 10.1002/hed.25325] [Medline: 29756245]</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_M9TT3dp">Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study</title>
		<author>
			<persName><forename type="first">F</forename><surname>Pacini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Ladenson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schlumberger</surname></persName>
		</author>
		<idno type="DOI">10.1210/jc.2005-1651</idno>
		<idno>Medline: 16384850</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_N6QJjcU">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="926" to="932" />
			<date type="published" when="2006-03">Mar 2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. Mar 2006;91(3):926-932. [doi: 10.1210/jc.2005-1651] [Medline: 16384850]</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_Jp46dA8">Opportunities to reduce potential bias in ophthalmic cost-utility analysis</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">C</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Chaudhry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Stein</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamaophthalmol.2020.6591</idno>
		<idno>Medline: 33538789</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FMce7RZ">JAMA Ophthalmol</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="389" to="397" />
			<date type="published" when="2021-04-01">Apr 1, 2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Brown GC, Brown MM, Chaudhry I, Stein JD. Opportunities to reduce potential bias in ophthalmic cost-utility analysis. JAMA Ophthalmol. Apr 1, 2021;139(4):389-397. [doi: 10.1001/jamaophthalmol.2020.6591] [Medline: 33538789]</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_MZKaQCd">Cost-effectiveness analysis of antithyroid drug therapy, 131I therapy and subtotal thyroidectomy for Graves&apos; disease</title>
		<author>
			<persName><forename type="first">F</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Watanabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hayashi</surname></persName>
		</author>
		<idno type="DOI">10.3769/radioisotopes.56.65</idno>
		<idno>Medline: 17766715</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4ACRAyg">Radioisotopes</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="65" to="76" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Yang F, Watanabe S, Hayashi K, et al. Cost-effectiveness analysis of antithyroid drug therapy, 131I therapy and subtotal thyroidectomy for Graves&apos; disease. Radioisotopes. 2007;56(2):65-76. [doi: 10.3769/radioisotopes.56.65] [Medline: 17766715]</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_MqXDfmC">Utility values associated with osteoporotic fracture: a systematic review of the literature</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hiligsmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Ethgen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Richy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Reginster</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00223-008-9117-6</idno>
		<idno>Medline: 18404243</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_432wYYW">Calcif Tissue Int</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="288" to="292" />
			<date type="published" when="2008-04">Apr 2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hiligsmann M, Ethgen O, Richy F, Reginster JY. Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int. Apr 2008;82(4):288-292. [doi: 10.1007/s00223-008-9117-6] [Medline: 18404243]</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_X2YFF9W">QALYs in cost-effectiveness analysis: an overview for cardiologists</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">J</forename><surname>Wouters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Naci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Samani</surname></persName>
		</author>
		<idno type="DOI">10.1136/heartjnl-2015-308255</idno>
		<idno>Medline: 26395316</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SA9uT6t">Heart</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page" from="1868" to="1873" />
			<date type="published" when="2015-12">Dec 2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wouters OJ, Naci H, Samani NJ. QALYs in cost-effectiveness analysis: an overview for cardiologists. Heart. Dec 2015;101(23):1868-1873. [doi: 10.1136/heartjnl-2015-308255] [Medline: 26395316]</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_xAaKAk6">Guidelines for economic evaluation of pharmaceuticals in Korea</title>
		<idno type="DOI">10.1017/s0009840x25000848</idno>
		<ptr target="https://repository.hira.or.kr/handle/2019.oak/2541" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_bRxU7vS">HIRA</title>
		<imprint>
			<date type="published" when="2021">2021. 2025-07-08</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Guidelines for economic evaluation of pharmaceuticals in Korea. HIRA. 2021. URL: https://repository.hira.or.kr/handle/ 2019.oak/2541 [Accessed 2025-07-08]</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_pb2HMPv">Cohort profile: the National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea</title>
		<author>
			<persName><forename type="first">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Park</surname></persName>
		</author>
		<idno type="DOI">10.1093/ije/dyv319</idno>
		<idno>Medline: 26822938</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_E5r47Yf">Int J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">15</biblScope>
			<date type="published" when="2017-04-01">Apr 1, 2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lee J, Lee JS, Park SH, et al. Cohort profile: the National Health Insurance Service-National Sample Cohort (NHIS- NSC), South Korea. Int J Epidemiol. Apr 1, 2017;46(2):e15. [doi: 10.1093/ije/dyv319] [Medline: 26822938]</note>
</biblStruct>

<biblStruct xml:id="b27">
	<monogr>
		<title level="m" type="main" xml:id="_AP8vgPJ">Data in number of deaths by region, sex, and age</title>
		<idno type="DOI">10.7465/jkdi.2021.32.5.1085</idno>
		<ptr target="https://kosis.kr/statHtml/statHtml.do?orgId=101&amp;tblId=DT_2KAA811&amp;conn_path=I3" />
		<imprint>
			<date type="published" when="2021">2021. 2021. 2025-05-23</date>
			<publisher>Korean Statistical Information Service</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Data in number of deaths by region, sex, and age; 2021. Korean Statistical Information Service. 2021. URL: https:// kosis.kr/statHtml/statHtml.do?orgId=101&amp;tblId=DT_2KAA811&amp;conn_path=I3 [Accessed 2025-05-23]</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_ccYCUcc">Whose preferences count?</title>
		<author>
			<persName><forename type="first">P</forename><surname>Dolan</surname></persName>
		</author>
		<idno type="DOI">10.1177/0272989x9901900416</idno>
		<idno>Medline: 10520686</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_MEJr45m">Med Decis Making</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="482" to="486" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dolan P. Whose preferences count? Med Decis Making. 1999;19(4):482-486. [doi: 10.1177/0272989X9901900416] [Medline: 10520686]</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_advsuNw">The disability paradox: high quality of life against all odds</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Albrecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Devlieger</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0277-9536(98)00411-0</idno>
		<idno>Medline: 10390038</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zts9YZ2">Soc Sci Med</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="977" to="988" />
			<date type="published" when="1999-04">Apr 1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Albrecht GL, Devlieger PJ. The disability paradox: high quality of life against all odds. Soc Sci Med. Apr 1999;48(8):977-988. [doi: 10.1016/s0277-9536(98)00411-0] [Medline: 10390038]</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_6jSGVJ9">Patient and general public preferences for health states: a call to reconsider current guidelines</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Versteegh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wbf</forename><surname>Brouwer</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.socscimed.2016.07.043</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9jfw5d7">Soc Sci Med</title>
		<imprint>
			<biblScope unit="volume">165</biblScope>
			<biblScope unit="page" from="66" to="74" />
			<date type="published" when="2016-09">Sep 2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Versteegh MM, Brouwer WBF. Patient and general public preferences for health states: a call to reconsider current guidelines. Soc Sci Med. Sep 2016;165:66-74. [doi: 10.1016/j.socscimed.2016.07.043]</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_zBvh8Mk">Measurement of health state utilities for economic appraisal</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Torrance</surname></persName>
		</author>
		<idno type="DOI">10.1016/0167-6296(86)90020-2</idno>
		<idno>Medline: 10311607</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hsCYfh5">J Health Econ</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="30" />
			<date type="published" when="1986-03">Mar 1986</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ. Mar 1986;5(1):1-30. [doi: 10. 1016/0167-6296(86)90020-2] [Medline: 10311607]</note>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<idno type="DOI">10.1017/s0009840x25000848</idno>
		<ptr target="https://spot.wooribank.com/pot/Dream?withyou=FXXRT0016" />
		<title level="m" xml:id="_vXk9PG7">The average exchange rate in 2022</title>
		<imprint>
			<publisher>WooriBank</publisher>
			<date type="published" when="2025-07-08">2025-07-08</date>
		</imprint>
	</monogr>
	<note type="raw_reference">The average exchange rate in 2022. WooriBank. URL: https://spot.wooribank.com/pot/Dream?withyou=FXXRT0016 [Accessed 2025-07-08]</note>
</biblStruct>

<biblStruct xml:id="b33">
	<monogr>
		<title level="m" type="main" xml:id="_wZTPTeU">Consumer Price Index</title>
		<author>
			<persName><surname>Kosis</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2023">2023</date>
			<publisher>Korean Statistical Information Service</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">KOSIS. Consumer Price Index. Korean Statistical Information Service; 2023.</note>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<title level="m" type="main" xml:id="_awQ6ba7">Research on methodologies for evidence-based healthcare decision-making process in korea</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Ahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Shin</surname></persName>
		</author>
		<ptr target="https://www.neca.re.kr/lay1/program/S1T11C145/report/view.do?seq=54" />
		<imprint>
			<date type="published" when="2010">2010. 2025-07-08</date>
			<publisher>NECA</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Ahn JH, Kim YH, Shin SJ, et al. Research on methodologies for evidence-based healthcare decision-making process in korea. NECA. 2010. URL: https://www.neca.re.kr/lay1/program/S1T11C145/report/view.do?seq=54 [Accessed 2025-07-08]</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_HcDMXrQ">27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 6. Cost effectiveness of assessment and management of risk factors</title>
		<author>
			<persName><forename type="first">L</forename><surname>Goldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Garber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Grover</surname></persName>
		</author>
		<idno type="DOI">10.1016/0735-1097(96)87734-5</idno>
		<idno>Medline: 8609317</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9sU3wgx">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1020" to="1030" />
			<date type="published" when="1996-04">Apr 1996</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Goldman L, Garber AM, Grover SA, et al. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 6. Cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol. Apr 1996;27(5):1020-1030. [doi: 10.1016/0735-1097(96)87734-5] [Medline: 8609317]</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_n8kGHVZ">International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?</title>
		<author>
			<persName><forename type="first">T</forename><surname>Shiroiwa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">K</forename><surname>Sung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fukuda</surname></persName>
		</author>
		<idno type="DOI">10.1002/hec.1481</idno>
		<idno>Medline: 19382128</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7BhYGq6">Health Econ</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="422" to="437" />
			<date type="published" when="2010-04">Apr 2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. Apr 2010;19(4):422-437. [doi: 10.1002/hec.1481] [Medline: 19382128]</note>
</biblStruct>

<biblStruct xml:id="b37">
	<monogr>
		<title level="m" type="main" xml:id="_TmthepA">Cost-effectiveness thresholds: economic and ethical issues</title>
		<author>
			<persName><forename type="first">A</forename><surname>Towse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pritchard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Devlin</surname></persName>
		</author>
		<ptr target="https://www.ohe.org/publications/cost-effectiveness-thresholds-economic-and-ethical-issues/" />
		<imprint>
			<date type="published" when="2002">2002. 2025-05-23</date>
			<publisher>OHE Monograph</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Towse A, Pritchard C, Devlin N. Cost-effectiveness thresholds: economic and ethical issues. OHE Monograph. 2002. URL: https://www.ohe.org/publications/cost-effectiveness-thresholds-economic-and-ethical-issues/ [Accessed 2025-05-23]</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_8fxnCe2">Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations</title>
		<author>
			<persName><forename type="first">D</forename><surname>Husereau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Drummond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Augustovski</surname></persName>
		</author>
		<idno type="DOI">10.1017/s0266462321001732</idno>
		<idno>Medline: 35007499</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_HPUAGdG">Int J Technol Assess Health Care</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">13</biblScope>
			<date type="published" when="2022-01-11">Jan 11, 2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Int J Technol Assess Health Care. Jan 11, 2022;38(1):e13. [doi: 10.1017/S0266462321001732] [Medline: 35007499]</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_YXuxBTQ">Digital therapeutic care apps with decision-support interventions for people with low back pain in Germany: cost-effectiveness analysis</title>
		<author>
			<persName><forename type="first">D</forename><surname>Lewkowicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Wohlbrandt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bottinger</surname></persName>
		</author>
		<idno type="DOI">10.2196/35042</idno>
		<idno>Medline: 35129454</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uWdbJwa">JMIR Mhealth Uhealth</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">35042</biblScope>
			<date type="published" when="2022-02-07">Feb 7, 2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lewkowicz D, Wohlbrandt AM, Bottinger E. Digital therapeutic care apps with decision-support interventions for people with low back pain in Germany: cost-effectiveness analysis. JMIR Mhealth Uhealth. Feb 7, 2022;10(2):e35042. [doi: 10. 2196/35042] [Medline: 35129454]</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main" xml:id="_9H72KT2">Cost-effectiveness of digital therapeutics for essential hypertension</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tanigawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41440-022-00952-x</idno>
		<idno>Medline: 35726085</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ghxNKY6">Hypertens Res</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1538" to="1548" />
			<date type="published" when="2022-10">Oct 2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nomura A, Tanigawa T, Kario K, et al. Cost-effectiveness of digital therapeutics for essential hypertension. Hypertens Res. Oct 2022;45(10):1538-1548. [doi: 10.1038/s41440-022-00952-x] [Medline: 35726085]</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main" xml:id="_UZ3ZuGV">American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Ross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Burch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Cooper</surname></persName>
		</author>
		<idno type="DOI">10.1089/thy.2016.0229</idno>
		<idno>Medline: 27521067</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_HAJeQdK">Thyroid</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1343" to="1421" />
			<date type="published" when="2016-10">2016. Oct 2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. Oct 2016;26(10):1343-1421. [doi: 10.1089/thy.2016.0229] [Medline: 27521067]</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main" xml:id="_jzPAfJ7">The long-term follow-up of patients with thionamide-treated Graves&apos; hyperthyroidism</title>
		<author>
			<persName><forename type="first">S</forename><surname>Bandai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Okamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fujikawa</surname></persName>
		</author>
		<idno type="DOI">10.1507/endocrj.EJ18-0418</idno>
		<idno>Medline: 30918165</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DzFNqFr">Endocr J. Jun</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="535" to="545" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bandai S, Okamura K, Fujikawa M, et al. The long-term follow-up of patients with thionamide-treated Graves&apos; hyperthyroidism. Endocr J. Jun 28, 2019;66(6):535-545. [doi: 10.1507/endocrj.EJ18-0418] [Medline: 30918165]</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main" xml:id="_3qVTkTm">Long-term continuous methimazole or radioiodine treatment for hyperthyroidism</title>
		<author>
			<persName><forename type="first">F</forename><surname>Azizi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Yousefi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bahrainian</surname></persName>
		</author>
		<idno type="DOI">10.1210/endo-meetings.2011.part2.p17.p1-682</idno>
		<idno>Medline: 22827783</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_mJ6PCUw">Arch Iran Med</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="477" to="484" />
			<date type="published" when="2012-08">Aug 2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Azizi F, Yousefi V, Bahrainian A, et al. Long-term continuous methimazole or radioiodine treatment for hyperthyroidism. Arch Iran Med. Aug 2012;15(8):477-484. [Medline: 22827783]</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main" xml:id="_5QyBpMg">Outcomes in relapsed Graves&apos; disease patients following radioiodine or prolonged low dose of methimazole treatment</title>
		<author>
			<persName><forename type="first">D</forename><surname>Villagelin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Romaldini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Santos</surname></persName>
		</author>
		<idno type="DOI">10.1089/thy.2015.0195</idno>
		<idno>Medline: 26414885</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fSQGTbU">Thyroid</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1282" to="1290" />
			<date type="published" when="2015-12">Dec 2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Villagelin D, Romaldini JH, Santos RB, et al. Outcomes in relapsed Graves&apos; disease patients following radioiodine or prolonged low dose of methimazole treatment. Thyroid. Dec 2015;25(12):1282-1290. [doi: 10.1089/thy.2015.0195] [Medline: 26414885]</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main" xml:id="_MRVEEVW">Outcome of very long-term treatment with antithyroid drugs in Graves&apos; hyperthyroidism associated with Graves&apos; orbitopathy</title>
		<author>
			<persName><forename type="first">L</forename><surname>Elbers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mourits</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wiersinga</surname></persName>
		</author>
		<idno type="DOI">10.1089/thy.2010.0181</idno>
		<idno>Medline: 21190446</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kpMKJ3m">Thyroid</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="279" to="283" />
			<date type="published" when="2011-03">Mar 2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Elbers L, Mourits M, Wiersinga W. Outcome of very long-term treatment with antithyroid drugs in Graves&apos; hyperthyroidism associated with Graves&apos; orbitopathy. Thyroid. Mar 2011;21(3):279-283. [doi: 10.1089/thy.2010.0181] [Medline: 21190446]</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main" xml:id="_jEeY3ru">Comparison of the long-term efficacy of low dose 131I versus antithyroid drugs in the treatment of hyperthyroidism</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Schneider</surname></persName>
		</author>
		<idno type="DOI">10.1097/mnm.0b013e3283134d4d</idno>
		<idno>Medline: 19194213</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_q7Zp85c">Nucl Med Commun</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="160" to="168" />
			<date type="published" when="2009-02">Feb 2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chen DY, Jing J, Schneider PF, et al. Comparison of the long-term efficacy of low dose 131I versus antithyroid drugs in the treatment of hyperthyroidism. Nucl Med Commun. Feb 2009;30(2):160-168. [doi: 10.1097/MNM. 0b013e3283134d4d] [Medline: 19194213]</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main" xml:id="_v4X37Z4">Long-term antithyroid drug treatment: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">F</forename><surname>Azizi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Malboosbaf</surname></persName>
		</author>
		<idno type="DOI">10.1089/thy.2016.0652</idno>
		<idno>Medline: 28699478</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5hg5Y5u">Thyroid</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1223" to="1231" />
			<date type="published" when="2017-10">Oct 2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Azizi F, Malboosbaf R. Long-term antithyroid drug treatment: a systematic review and meta-analysis. Thyroid. Oct 2017;27(10):1223-1231. [doi: 10.1089/thy.2016.0652] [Medline: 28699478]</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main" xml:id="_scBnqPb">Long-term antithyroid drug treatment of patients with Graves&apos; disease</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Cooper</surname></persName>
		</author>
		<idno type="DOI">10.1089/ct.2019;31.230-233</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BFycRCu">Clin Thyroidol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="230" to="233" />
			<date type="published" when="2019-06">Jun 2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cooper DS. Long-term antithyroid drug treatment of patients with Graves&apos; disease. Clin Thyroidol. Jun 2019;31(6):230-233. [doi: 10.1089/ct.2019;31.230-233]</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main" xml:id="_baagPuq">European Thyroid Association guideline for the management of Graves&apos; hyperthyroidism</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Kahaly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bartalena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hegeds</surname></persName>
		</author>
		<idno type="DOI">10.1159/000490384</idno>
		<idno>Medline: 30283735</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_U9JRkyN">Eur Thyroid J</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="167" to="186" />
			<date type="published" when="2018-08">2018. Aug 2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kahaly GJ, Bartalena L, Hegeds L, et al. 2018 European Thyroid Association guideline for the management of Graves&apos; hyperthyroidism. Eur Thyroid J. Aug 2018;7(4):167-186. [doi: 10.1159/000490384] [Medline: 30283735]</note>
</biblStruct>

<biblStruct xml:id="b50">
	<monogr>
		<title level="m" type="main" xml:id="_HAPcCeU">Adherence to long-term therapies:evidence for action</title>
		<idno type="DOI">10.1007/bf03083829</idno>
		<ptr target="https://digicollections.net/medicinedocs/#d/s4883e" />
		<imprint>
			<date type="published" when="2003">2003. 2024-06-28</date>
			<publisher>World Health Organization</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">World Health Organization. Adherence to long-term therapies:evidence for action. 2003. URL: https://digicollections. net/medicinedocs/#d/s4883e [Accessed 2024-06-28]</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main" xml:id="_AMdRenD">Improving medication adherence through adaptive digital interventions (iMedA) in patients with hypertension: protocol for an interrupted time series study</title>
		<author>
			<persName><forename type="first">K</forename><surname>Etminani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gransson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Galozy</surname></persName>
		</author>
		<idno type="DOI">10.2196/24494</idno>
		<idno>Medline: 33978593</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_AhmbPJZ">JMIR Res Protoc</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page">24494</biblScope>
			<date type="published" when="2021-05-12">May 12, 2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Etminani K, Gransson C, Galozy A, et al. Improving medication adherence through adaptive digital interventions (iMedA) in patients with hypertension: protocol for an interrupted time series study. JMIR Res Protoc. May 12, 2021;10(5):e24494. [doi: 10.2196/24494] [Medline: 33978593]</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main" xml:id="_pCgxqnQ">Digital medication adherence support: could healthcare providers recommend mobile health apps?</title>
		<author>
			<persName><forename type="first">C</forename><surname>Backes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Moyano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rimaud</surname></persName>
		</author>
		<idno type="DOI">10.3389/fmedt.2020.616242</idno>
		<idno>Medline: 35047896</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wsFawFS">Front Med Technol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">616242</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Backes C, Moyano C, Rimaud C, et al. Digital medication adherence support: could healthcare providers recommend mobile health apps? Front Med Technol. 2020;2:616242. [doi: 10.3389/fmedt.2020.616242] [Medline: 35047896]</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main" xml:id="_ZkxfjWj">Monitoring adherence to asthma inhalers using the InspirerMundi app: analysis of real-world, medium-term feasibility studies</title>
		<author>
			<persName><forename type="first">C</forename><surname>Jcome</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Almeida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Pereira</surname></persName>
		</author>
		<idno type="DOI">10.3389/fmedt.2021.649506</idno>
		<idno>Medline: 35047915</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fSWVAEg">Front Med Technol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">649506</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jcome C, Almeida R, Pereira AM, et al. Monitoring adherence to asthma inhalers using the InspirerMundi app: analysis of real-world, medium-term feasibility studies. Front Med Technol. 2021;3:649506. [doi: 10.3389/fmedt.2021.649506] [Medline: 35047915]</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main" xml:id="_kHJz8Ah">Do mobile device apps designed to support medication adherence demonstrate efficacy? A systematic review of randomised controlled trials, with meta-analysis</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Armitage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kassavou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sutton</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2019-032045</idno>
		<idno>Medline: 32005778</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2b5JFS5">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">32045</biblScope>
			<date type="published" when="2020-01-30">Jan 30, 2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Armitage LC, Kassavou A, Sutton S. Do mobile device apps designed to support medication adherence demonstrate efficacy? A systematic review of randomised controlled trials, with meta-analysis. BMJ Open. Jan 30, 2020;10(1):e032045. [doi: 10.1136/bmjopen-2019-032045] [Medline: 32005778]</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
